- Home
- CLGN vs RAVE Comparison
CLGN vs RAVE Comparison
Compare CLGN & RAVE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CLGN
- RAVE
- Stock Information
- Founded
- CLGN 2004
- RAVE 1958
- Country
- CLGN Israel
- RAVE United States
- Employees
- CLGN N/A
- RAVE N/A
- Industry
- CLGN Industrial Specialties
- RAVE Restaurants
- Sector
- CLGN Health Care
- RAVE Consumer Discretionary
- Exchange
- CLGN Nasdaq
- RAVE Nasdaq
- Market Cap
- CLGN 37.4M
- RAVE N/A
- IPO Year
- CLGN N/A
- RAVE N/A
- Fundamental
- Price
- CLGN $2.58
- RAVE $2.75
- Analyst Decision
- CLGN Strong Buy
- RAVE
- Analyst Count
- CLGN 2
- RAVE 0
- Target Price
- CLGN $12.50
- RAVE N/A
- AVG Volume (30 Days)
- CLGN 12.3K
- RAVE 17.3K
- Earning Date
- CLGN 03-26-2025
- RAVE 05-01-2025
- Dividend Yield
- CLGN N/A
- RAVE N/A
- EPS Growth
- CLGN N/A
- RAVE 37.66
- EPS
- CLGN N/A
- RAVE 0.18
- Revenue
- CLGN $515,000.00
- RAVE $12,236,000.00
- Revenue This Year
- CLGN $2,474.76
- RAVE N/A
- Revenue Next Year
- CLGN $52.63
- RAVE N/A
- P/E Ratio
- CLGN N/A
- RAVE $15.43
- Revenue Growth
- CLGN N/A
- RAVE 3.25
- 52 Week Low
- CLGN $2.54
- RAVE $1.70
- 52 Week High
- CLGN $6.75
- RAVE $3.36
- Technical
- Relative Strength Index (RSI)
- CLGN 26.97
- RAVE 48.48
- Support Level
- CLGN $2.54
- RAVE $2.60
- Resistance Level
- CLGN $3.70
- RAVE $3.10
- Average True Range (ATR)
- CLGN 0.26
- RAVE 0.15
- MACD
- CLGN -0.04
- RAVE -0.02
- Stochastic Oscillator
- CLGN 3.45
- RAVE 30.00
About CLGN CollPlant Biotechnologies Ltd
CollPlant Biotechnologies Ltd is a regenerative and aesthetic medicine company focused on 3D bioprinting of tissues and organs and medical aesthetics. Its products are based on its rhCollagen (recombinant human collagen) produced with CollPlant's proprietary plant based genetic engineering technology. These products address indications for the diverse fields of tissue repair, aesthetics, and organ manufacturing. The revenues include income from business collaborators and sales of the BioInk product for the development of 3D bioprinting of organs and tissues, sales of rhCollagen for the medical aesthetics market, and sales in Europe of the products for tendinopathy and wound healing. The company operates in United States, which derives key revenue, Canada, Europe and Other, and Israel.